Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial - PubMe
3 hours ago
- #revascularization
- #rivaroxaban
- #peripheral artery disease
- The VOYAGER-PAD trial studied low-dose rivaroxaban plus aspirin in PAD patients undergoing lower extremity revascularization (LER).
- Patients with prior LER had a higher risk of major adverse limb events (MALE) compared to those without prior LER (12.9% vs. 8.0% at 3 years).
- Rivaroxaban reduced the primary efficacy endpoint (composite of acute limb ischemia, major amputation, MI, ischemic stroke, or CV death) more in patients with prior LER (HR 0.73) than without (HR 0.94).
- The relative increase in major bleeding with rivaroxaban was consistent regardless of prior LER status.
- Patients with prior LER are at particularly high risk of MALE, and rivaroxaban showed greater relative benefit in this group.